Anhedonia — the diminished capacity to anticipate or experience pleasure — affects millions of people with depression, schizophrenia, and other neuropsychiatric conditions, yet it remains one of psychiatry's most treatment-resistant symptoms. Understanding why requires dismantling a decades-old assumption: that blunted dopamine signaling is the central culprit. A rigorous expert consensus process now suggests the reality is considerably more complex.
This ECNP-GALENOS consensus report synthesizes current evidence and defines a formal research agenda around anhedonia's multiple distinct facets: anticipatory 'wanting,' consummatory 'liking,' effort allocation, reward learning, and social and physical engagement. While phasic dopaminergic signaling is implicated in anticipation, motivation, and reward learning, a key meta-analytic finding driving this agenda is that prodopaminergic antidepressants — including bupropion and related agents — yield only modest improvements in anhedonia symptoms. This challenges the field to investigate mechanisms beyond the mesolimbic dopamine pathway, including opioid, glutamatergic, and inflammatory systems. The report calls for a biologically-informed translational nomenclature to align animal models, neuroimaging paradigms, and clinical measures — currently fragmented across research programs — into a coherent framework.
This consensus arrives at a pivotal moment. The field's growing recognition that major depression is neurobiologically heterogeneous makes symptom-level precision targeting increasingly important. Anhedonia, as a transdiagnostic dimension spanning depression, schizophrenia, and addiction, is a particularly high-value target. Yet the clinical measurement tools remain inadequate: self-report scales collapse distinct reward sub-processes into single scores, obscuring which biological mechanism is actually impaired in a given patient. The call for multimodal measurement — integrating neuroimaging, electrophysiology, and liquid biomarkers — signals a meaningful methodological leap. Whether this ambitious agenda translates into actionable diagnostics and targeted therapies within a decade will depend heavily on funding continuity and cross-institutional collaboration. As a framework-setting document from a major European neuroscience body, this report carries significant influence over the next generation of clinical trial design.